These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 23360848)

  • 1. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
    Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
    Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
    Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
    Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
    Rahmani M; Reese E; Dai Y; Bauer C; Payne SG; Dent P; Spiegel S; Grant S
    Cancer Res; 2005 Mar; 65(6):2422-32. PubMed ID: 15781658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
    Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
    Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.
    Locatelli SL; Cleris L; Stirparo GG; Tartari S; Saba E; Pierdominici M; Malorni W; Carbone A; Anichini A; Carlo-Stella C
    Leukemia; 2014 Sep; 28(9):1861-71. PubMed ID: 24561519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
    Kim MN; Ro SW; Kim DY; Kim da Y; Cho KJ; Park JH; Lim HY; Han KH
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):257-67. PubMed ID: 26037205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells.
    Xiao RZ; He CM; Xiong MJ; Ruan XX; Wang LL; Chen Y; Lin DJ
    Oncol Rep; 2013 May; 29(5):1895-901. PubMed ID: 23467984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism.
    Chiarini F; Del Sole M; Mongiorgi S; Gaboardi GC; Cappellini A; Mantovani I; Follo MY; McCubrey JA; Martelli AM
    Leukemia; 2008 Jun; 22(6):1106-16. PubMed ID: 18385752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
    Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
    Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.
    Carlo-Stella C; Locatelli SL; Giacomini A; Cleris L; Saba E; Righi M; Guidetti A; Gianni AM
    PLoS One; 2013; 8(4):e61603. PubMed ID: 23620775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines.
    Dasmahapatra GP; Didolkar P; Alley MC; Ghosh S; Sausville EA; Roy KK
    Clin Cancer Res; 2004 Aug; 10(15):5242-52. PubMed ID: 15297428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway.
    Lin MT; Lin CL; Lin TY; Cheng CW; Yang SF; Lin CL; Wu CC; Hsieh YH; Tsai JP
    Tumour Biol; 2016 May; 37(5):6987-96. PubMed ID: 26662956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
    Momota H; Nerio E; Holland EC
    Cancer Res; 2005 Aug; 65(16):7429-35. PubMed ID: 16103096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
    BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination treatment with perifosine and MEK-162 demonstrates synergism against lung cancer cells in vitro and in vivo.
    Zhang J; Hong Y; Shen J
    Tumour Biol; 2015 Jul; 36(7):5699-706. PubMed ID: 25697899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
    Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
    Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perifosine sensitizes curcumin-induced anti-colorectal cancer effects by targeting multiple signaling pathways both in vivo and in vitro.
    Chen MB; Wu XY; Tao GQ; Liu CY; Chen J; Wang LQ; Lu PH
    Int J Cancer; 2012 Dec; 131(11):2487-98. PubMed ID: 22438101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
    Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI
    Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.